These discrepancies may be explained by the evaluation of a group of patients of mixed metabolic disease statuses in these studies, complicating the evaluation of serum VEGF levels, as serum VEGF levels are induced by insulin and hyperglycemia (4,17). The gene discussed is INS; the disease is metabolic disease.